Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06704347 · ClinicalTrials.gov registry record · Phase 1
Safety Study of XT-150 in Participants With ALS
A Phase 1 study, sponsored by Xalud Therapeutics.
- Not yet
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT06704347: Clinical Trial Phase 1 study, sponsored by Xalud Therapeutics.
NCT06704347 is a Phase 1 study that has not yet begun recruiting, run by Xalud Therapeutics. The registered enrollment target is 8 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (87% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06704347, a Phase 1 study, has not yet begun recruiting, sponsored by Xalud Therapeutics.
- NOT YET RECRUITING
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
This is a Phase 1, open-label, multi-center safety study of XT-150 in adult participants with Amyotrophic Lateral Sclerosis (ALS). Participants providing informed consent and meeting all study eligibility criteria will be enrolled in the study and will receive a single injection of XT-150 at the Baseline visit. Follow-up visits will occur over 180 days (6 months) after the injection. 8 participants (4 participants per dose level) will be enrolled sequentially in up to 2 ascending, single dose cohorts: Cohort 1: 1.5 mg XT-150 Cohort 2: 4.5 mg XT-150
Interventions
- BIOLOGICAL XT-150
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2025-11 |
| Est. Completion | 2027-03 |
| Phase | Phase 1 |
What is known before NCT06704347 opens enrollment
NCT06704347 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (87% lower).
The record links to 0 conditions, and to 1 intervention - of which XT-150 is the first listed.
NCT06704347 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06704347 about?
NCT06704347 is a clinical study titled "Safety Study of XT-150 in Participants With ALS". This is a Phase 1, open-label, multi-center safety study of XT-150 in adult participants with Amyotrophic Lateral Sclerosis (ALS). Participants providing informed consent and meeting all study eligibility criteria will be enrolled in the study and will receive a single injection of XT-150 at the Ba...
What is the current status of trial NCT06704347?
This trial is currently not yet recruiting. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2025-11. Estimated completion is 2027-03.
What interventions are being tested in trial NCT06704347?
The interventions under investigation include: XT-150 (BIOLOGICAL).
Who is sponsoring clinical trial NCT06704347?
This trial is sponsored by Xalud Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06704347's enrollment target sits among peer trials
8 1959th of 2000 higher than 29 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia